Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL184 in Recurrent Glioblastoma Multiforme
NCT00704288Phase 2Completed
- Sponsor
- Exelixis, Inc.
- Start
- May 2008
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in glioblastoma multiforme (GBM), sponsored by Exelixis, Inc.. Started May 2008; status: completed.
02
Drugs
cabozantinib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00704288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704288.